CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03430947
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:35.417944+00:00
Published At: 2023-09-14T00:00:00+00:00
Record Updated At: 2023-09-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Melanoma Stage IV", "BRAF V600 Mutation", "Brain Metastases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-09-14"
protocolSection.identificationModule.nctId: "NCT03430947"
protocolSection.identificationModule.officialTitle: "An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf\u00ae) Plus Cobimetinib (Cotellic\u00ae) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.